Efficacy of Clomipramine, Sertraline and Terazosin Treatments in Premature Ejaculation
Aim: To compare the efficacy of oral clomipramine, sertraline and terazosin to placebo in premature ejaculation. Materials and Methods: A total of 90 patients aged from 20 to 58 years were enrolled in this study. Patients were randomized into 4 groups. Group 1 (n: 22) took placebo and served as controls. Group 2 (n: 23) patients took 25 mg clomipramine HCl nightly; Group 3 (n: 20) 50 mg sertraline nightly; and Group 4 (n: 25) 5 mg terazosin nightly. The medications were used for two months. After 8 sexual attempts, the patients' clinical responses were assessed using the patient self-description method. Clinical responses were classified as ``no change´´, ``improvemen´´ and ``under contro´´. Success was described as improvement + under control. Results: Success rates were 36.3% in Group 1, 91.3% in Group 2, 90% in Group 3 and 76% in Group 4. Although the efficacy of each medical treatment was superior to placebo (P = 0.001), no significant difference in efficacy was found between the medical treatment groups (P = 0.537). Conclusions: Clomipramine, sertraline and terazosin are more efficient than placebo. No significant difference was observed in terms of efficacy among these three medical treatments.
Efficacy of Clomipramine, Sertraline and Terazosin Treatments in Premature Ejaculation
Aim: To compare the efficacy of oral clomipramine, sertraline and terazosin to placebo in premature ejaculation. Materials and Methods: A total of 90 patients aged from 20 to 58 years were enrolled in this study. Patients were randomized into 4 groups. Group 1 (n: 22) took placebo and served as controls. Group 2 (n: 23) patients took 25 mg clomipramine HCl nightly; Group 3 (n: 20) 50 mg sertraline nightly; and Group 4 (n: 25) 5 mg terazosin nightly. The medications were used for two months. After 8 sexual attempts, the patients' clinical responses were assessed using the patient self-description method. Clinical responses were classified as ``no change´´, ``improvemen´´ and ``under contro´´. Success was described as improvement + under control. Results: Success rates were 36.3% in Group 1, 91.3% in Group 2, 90% in Group 3 and 76% in Group 4. Although the efficacy of each medical treatment was superior to placebo (P = 0.001), no significant difference in efficacy was found between the medical treatment groups (P = 0.537). Conclusions: Clomipramine, sertraline and terazosin are more efficient than placebo. No significant difference was observed in terms of efficacy among these three medical treatments.
___
- Spiess WF, Geer JH, O’Donohue WT. Premature ejaculation: investigation of factors in ejaculatory latency. J Abnorm Psychol 1984; 93: 242-5.
- Strassberg DS, Mahoney JM, Schaugaard M, Hale VE. The role of anxiety in premature ejaculation: a psychophysiological model. Arch Sex Behav 1990; 19: 251-7.
- Colpi GM, Fanciullacci F, Beretta G, Negri L, Zanollo A. Evoked sacral potentials in subjects with true premature ejaculation. Andrologia 1986; 18: 583-6.
- Jannini EA, Simonelli C, Lenzi A. Disorders of ejaculation. J Endocrinol Invest 2002; 25: 1006-19.
- Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369-81.
- Schuster TG, Ohl DA. Diagnosis and treatment of ejaculatory dysfunction. Urol Clin North Am 2002; 29: 939-48.
- Lorrain DS, Matuszewich L, Friedman RD, Hull EM. Extracellular serotonin in the lateral hypothalamic area is increased during the postejaculatory interval and impairs copulation in male rats. J Neurosci 1997; 17: 9361-6.
- Waldinger MD, Olivier B. Selective serotonin reuptake inhibitor- induced sexual dysfunction. Clinical and research considerations. Int Clin Psychopharmacol 1998; 13 (Suppl. 6): S27-S33.
- Berendsen H, Broekkamp C. Behavioural evidence for functional interactions between 5-HT receptor sub-types in rats and mice. Br J Pharmacol 1990; 101: 667-73.
- Yells DP, Prendergast MA, Hendricks SE, Nakamura M. Fluoxetine induced inhibition of male rat copulatory behavior: modification by lesions of the nucleus paragigantocellularis. Pharmacol Biochem Behav 1994; 49: 121-7.
- Kim SW, Lee SH, Paick J-S. In vivo rat model to measure hypogastric nerve-stimulation-induced seminal vesicle and vasal pressure responses simultaneously. Int J Impot Res 2004; 16: 427-32.
- Segraves RT, Saran A, Segraves K, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther 1993; 19: 198-200.
- Haensel SM, Rowland DL, Kallan KT, Slob AK. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol 1996; 156: 1310-5.
- McMahon CG, Ramin S. Pharmacological treatment of premature ejaculation. Curr Opin Urol 1999; 9: 553-61.
- Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. J Clin Psychopharmacol 1995; 15: 341-6.
- Balbay MD, Yildiz M, Salvarci A, Ozsan O, Ozbek E. Treatment of premature ejaculation with sertraline. Int Urol Nephrol 1998; 30: 81-3.
- McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159: 1935-8.
- Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double- blind, placebo-controlled study. J Urol 1998; 159: 425-7.
- Teng CM, Guh JH, Ko FN. Functional identification of alpha- adrenoreceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. Eur J Pharmacol 1994; 265: 61-6.
- Pupo AS. Functional effects of castration on alpha1- adrenoreceptors in rat vas deferens. Eur J Pharmacol 1998; 351: 217-23.
- Silva MA, Megale A, Avellar MCW, Porto CS. Expression and pharmacological characterization of alpha1-adrenoreceptors in rat seminal vesicle. Eur J Pharmacol 1999; 381: 141-9.
- Debruyne FM, Van der Poel HG. Clinical experience in Europe with uroselective alpha 1-antagonists. Eur Urol 1999; 36 (Suppl 1): 54-8.